Log in to your Inderes Free account to see all free content on this page.
Bonesupport
275.2 SEK +0.22%7 investors are following this company
Bone Support is active in medical technology. The company develops and commercializes injectable bioceramic bone graft substitutes that are transformed into the patient's bone and have the ability to release drugs. The company's bone graft substitutes are based on the technology platform Cerament. At present, the company conducts ongoing clinical studies. The company has sales in Europe and North America and is headquartered in Lund, Sweden.
Revenue
-
EBIT %
-
P/E
73
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
BONEX
Daily low / high price
263 / 275.2
SEK
Market cap
18.35B SEK
Turnover
50.85M SEK
Volume
188K
Latest videos
Financial calendar
Interim report
24.10.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
HealthCap | 9.9 % | 10.0 % |
Swedbank Robur Fonder | 9.3 % | 9.4 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Redeye: BONESUPPORT Q2 - Strong development, but more leg room for the share
![Bonesupport, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/17a391ef-648a-4471-88f4-8591da40cce5.png)
Bonesupport, Audiocast with teleconference, Q2'24
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
BONESUPPORT HOLDING AB (publ) – publishes Q2 2024 Interim report
Modular Finance IR Consensus: BONESUPPORT – Consensus estimates Q2 2024
BONESUPPORT HOLDING AB (publ) – Invitation to conference call and webcast for Interim report Q2 2024
The market submission for CERAMENT® V in the US will be a 510(k)
BONESUPPORT™ APPOINTS ANNA STEGMARK EVP QM & RA
CERAMENT® contributes to fewer amputations – new data from Australia
BULLETIN FROM THE ANNUAL SHAREHOLDERS’ MEETING IN BONESUPPORT HOLDING AB ON 16 MAY 2024
Redeye: BONESUPPORT Q1 - Short-sighted reaction on solid report
![Bonesupport, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/de751c8e-5bdf-4e3d-ac34-1d789c06cb37.png)